Sponsored by VisionaryHealthConcepts  

(creators of www.freehivinfo.com)  

 

 

 

HCV Articles

 

Hepatitis C cases in New York expected to soar in a decade; 1 in 24 New Yorkers have hepatitis C: 340,000 in NYS (Mar 31, 2008)

 

Alcohol, Tobacco, and Cannabis All May Promote Liver Disease Progression in People with Chronic Hepatitis C (Mar 28, 2008)

 

U.S. hepatitis C soars in those over 45  (Mar 26, 2008)

 

HCV Death Rates 50% Underestimated  (Mar 26, 2008) 

 

UNOS Liver Transplant Waiting List: Is it a Scandal?  (Mar 24, 2008)  
 

Blood donations down after Las Vegas hepatitis C scare (Mar 15, 2008)

 

HCV In Las Vegas- PUBLIC HEALTH CRISIS: Lawyers: 100 fear infection  (Mar 10, 2008)

 

Glucose >100 mg/dl Reduces Interferon/RBV SVR  (Mar 10, 2008)
 
PBMC Not A Reservoir for HCV for Patients Who Clear HCV RNA, Study Reports  (Mar 7, 2008)
 
Changing trends in hepatitis C-related mortality in the United States, 1995-2004
 (Mar 6, 2008)

 

FibroScan for Diagnosis of Fibrosis in Patients with Acute Viral Hepatitis and Recurrent Hepatitis C (Mar 4, 2008)

 

CDC Warns of Safety Problems at Clinics (Mar 4, 2008)

 

New Upper Limit Defined for Normal ALT in Adolescent Males (Feb 26, 2008)

 

Genetic Variations in HCV Genotype 3 Core Protein Promote Liver Fat Accumulation (Feb 26, 2008)

 

Decreased bone mineral density after therapy with alpha interferon in combination with ribavirin for chronic hepatitis C (Feb 22, 2008)

 
Proteomic profiling shown more accurate than traditional biomarkers in identifying liver cancer  
(Feb 20, 2008)

 

Asians with HCV Genotype 3 Do Not Respond as Well as Caucasians to Interferon-based Therapy (Feb 19, 2008)

 

Naringenin Compound in Grapefruit Inhibits HCV Replication in Laboratory Study (Feb 15, 2008)

 

Grapefruit Compound May Help Combat Hepatitis C Infection (Feb 4, 2008)

 

MGH study reveals mechanism key to maintaining chronic infection, potential therapy target. Massachusetts General Hospital  Press release. (Feb 4, 2008)

Apolipoprotein B dependent hepatitis C virus secretion is inhibited by the grapefruit flavonoid naringenin. Hepatology. (Jan 7, 2008)

 

Influence of Cannabis Use on Severity of Hepatitis C Disease  (Jan 29, 2008)

 

Daily cannabis use associated with worse fibrosis in patients with chronic hepatitis C (Jan 29, 2008)


 Global Challenges - British Soldiers, Civilian Contractors Undergo HIV, Hepatitis C Screenings After Receiving Blood That Was Not Properly Screened (Jan 15, 2008)

 

Treatment of Hepatitis C Reduces Incidence of Non-Hodgkin's Lymphoma  (Jan 23, 2008)

 

First large head-to-head comparison of Schering and Roche HCV therapies: similar virologic responses; fewer relapses with PegIntron  (Jan 16, 2008)

 

IDEAL Study COMMENTARY- Doug Dieterich MD A Healthy Dose of Curiosity Clinical trial results require careful interpretation  (Jan 14, 2008)

 

Join Hepatitis C Advocates UNITED! (Aug 7, 2007)

 

Improved cognitive function as a consequence of hepatitis C virus treatment  (Nov 15, 2007)

 

AASLD- High rates of sustained virologic response (SVR) in patients >50 years infected with HCV genotype 1 with positive prognostic factors treated with peginterferon alfa-2a (40KD) (PEGASYS®) and ribavirin (COPEGUS®)  (Nov 13, 3/07)

 

AASLD-Tibotec HCV Protease Inhibitor  (Nov 9, 2007)

 

UK report highlights homelessness link to IDUs acquiring hepatitis C, but not HIV  (Nov 1, 2007)

 

HPA’s ‘Shooting Up: Infections Among Injecting Drug Users in the United Kingdom 2006. An update: 2007  (released October 2007)

 

EACS: Studies underline the need for better hepatitis C treatment (November 2, 2007)

 

Adherence to Hepatitis C Treatment among Recovering Heroin Users on Methadone Maintenance (Oct 23, 2007)

 

Interferon/ribavirin Decreases Liver Enzyme Levels and May Enable Re-initiation of Antiretroviral Therapy in HIV-HCV Coinfected Patients with HAART-related Liver Injury (Oct 15, 2007)

 

Combination Therapy with HCV Protease Inhibitor Boceprevir Produces a High Rate of Early Virological

 Response in Genotype 1 Hepatitis C Patients  (Oct 10, 2007)

 

"True" weight-based dosing versus "flat' dosing of ribavirin: Will the WIN-R please come forward? Editorial  (Oct 3, 2007)
 
Peginterferon alfa-2b and weight-based or flat-dose ribavirin in chronic hepatitis C patients: A randomized trial (Oct 3, 2007)


Impact of weight-based ribavirin with peginterferon alfa-2b in african americans with hepatitis C virus genotype (Oct 3, 2007)

Sexual transmission of hepatitis C in HIV-positive gay men reported in Australia (Sep 24, 2007)

 

Possible Hepatitis C vaccine (Sep 5, 2007)

 

New therapies for hepatitis C: VX-950 (telaprevir)  (Sep 11, 2007)

 

IAS: Rectal trauma and drug use key in sexual transmission of HCV (Aug 3, 2007)

 

IAS: HCV therapy does not significantly effect immune recovery of patients taking HIV therapy (Aug 3, 2007)

 

IAS: Rectal trauma and drug use key in sexual transmission of HCV (Aug 3, 2007)

 

OraSure Technologies Announces Pre-Clinical Study Results for Prototype Rapid HCV Antibody Test at AACC Annual Meeting  (Jul 20, 2007)

 

Treatment of chronic hepatitis C virus genotype 1 with peginterferon, ribavirin, and epoetin alpha - (Jul 16, 2007)
 
The effects of discontinuing pioglitazone in patients with nonalcoholic steatohepatitis - (Jul 16, 2007)
 
Novartis, Idenix Suspend Tests on Hepatitis C Drug NM283 - (Jul 16, 2007)

 

Valopicitabine (HCV Polymerase inhibitor) Development Program Placed on Clinical Hold in the United States
(Jul 13, 2007)

Webcast Presentation Help

Click here for webcast

 

DDW: Risk of liver-related deaths from HBV, HCV and HBV/HCV coinfection (May 26/2007)

 

DDW: Does Attainment of Sustained Virologic Response (SVR) from Treatment of HCV Constitute a Cure? (June 1, 2007) 

 

DDW:  A Follow-up Week 12 Viral Count Is Useful in Predicting SVR and Is 100% Accurate in Patients without Cirrhosis (June 1, 2007) 

 

DDW: Treatment of Chronic Hepatitis C in Older Patients (June 1, 2007) 

DDW: Asians with Genotype 1 HCV Respond as Well as Whites to Interferon-based Therapy (May 25, 2007)

 

DDW: Statins Improve Sustained Response to Interferon-based Therapy in Small Study (May 25, 2007)

 

DDW: Novel HCV Protease Inhibitor Promising in Early Trial (May 24, 2007)

 

DDW: Relapsed HCV Patients Achieve Sustained Response with 72-Week Treatment (May 22, 2007)

 

DDW: Relapsed HCV Patients Achieve Sustained Response with 72-Week Treatment  (May 22, 2007)

 

DDW: Hepatitis Patients at Risk for Accidental Acetaminophen Toxicity (May 22, 2007)

 

DDW: Contrary to Common Wisdom, Statins May Offer Liver Benefit (May 20,2007)

 

Early Treatment With Three Classes of Antiretrovirals Quickly Reduces Viral Loads, Study Says (May 18, 2007)

 

 

EASL: In vitro Resistance Selection to the HCV Nucleoside Polymerase Inhibitor R1479 (R1626) and to the Protease Inhibitor VX-950  (Apr 23, 2007)


EASL: SVR Durable (99%) After 5 Years of Followup  (Apr 23, 2007)


EASL: 48 Weeks & High Ribavirin Dose May Improve SVR Rates for Genotype 2/3, French study by Bernard Willems  (Apr 23, 2007)


EASL: In Patients Who Clear HCV RNA At Week 12 (between week 8 and 12): SVR is Higher After 72 Weeks Than After 48 Weeks Treatment: Results of a Randomized Controlled Trial  (Apr 23, 2007)


EASL: New HCV Drug Target NS4A Antagonists  (Apr 23, 2007)

 

EASL: 14 Weeks vs 24 Weeks Peg/RBV for Genotypes 2/3  (Apr 20, 2007)
 

EASL: NM283 in Treatment-Naives Looks Better - (Apr 13 2007)

 

EASL: NM283, HCV Polymerase Inhibitor in Non-Responders - (Apr 13 2007) 


EASL: Omega-3 fatty acids alleviate chemically induced acute hepatitis by suppression of cytokines - (Apr 13 2007)

 

EASL: Resistance to New HCV Antivirals - (Apr 13 2007)

 

EASL: Vertex Pharmaceuticals Announces New Data for Investigational HCV Protease Inhibitor Telaprevir to be Presented at 42nd Annual Meeting of the European Association for the Study of the Liver (EASL) - (Apr 13 2007)

 

Response to HCV re-treatment predicted at 4 and 12 weeks (May 10, 2007)

 

CROI: Sexual transmission of HCV not limited to HIV-positive gay men (Mar 12, 2007)

Acute Hepatitis C in Men Who Have Sex With Men Is Not Confined to Those Infected with HIV, and Their Number Continues to Increase (Feb 28, 2007)

Pharmacokinetics of Boosted PI and NNRTI in HCV/HIV-co-infected Patients (Feb 28, 2007)

LDL Cholesterol Levels and Amino Acid Substitutions Predict Treatment Response (Feb 27, 2007)

 

News items preceded by “Drug Resistance Wksp:” is from the XV International HIV Drug Resistance Workshop
June 13-17, 2006  Sitges, Spain

 

Different Signaling Pathways in Patients with Hepatitis B and C
 

Integrating Medical and Mental Health Care Improves Likelihood of Initiation and Adherence to Hepatitis C Treatment (11/21/2006)
 

Hepatitis C Management Recommendations from the Department of Veterans Affairs (11/21/2006)

 

AASLD: Caffeine Linked to Reduced Histological Activity in People with Hepatitis C (11/17/2006)
 

AASLD: Virological Suppression and Occurrence of Anemia in Hepatitis C Patients Treated with Taribavirin (11/17/2006)
 

Lower Dose of Valopicitabine plus Pegylated Interferon Shows Antiviral Activity with Fewer Side Effects (11/10/2006)

 

Roche Polymerase Inhibitor R1626 Demonstrates Antiviral Activity and Good Safety in Phase I Study (11/10/2006)

 

Preclinical Study Shows ITMN-191 Plus Pegasys is Active against HCV In Vitrox(11/10/2006)

 

Pancaspase Inhibitor PF-03491390 Reduces ALT and AST Levels in Hepatitis C Patients (11/10/2006)

 

HCV RNA Negativity after 12 Weeks of Therapy Is the Best Predictor of SVR in Re-Treatment of Non-Responders: The EPIC3 Program (11/03/2006)

 

Response to PegIntron and Ribavirin in HCV Patients with Body Weight >125 kg: the WIN-R Trial (11/03/2006)

 

Risk Factors for Relapse in Patients with High Viral Load and Genotype 3 Hepatitis C in the WIN-R Trial (11/03/2006)

 

Pegasys plus Ribavirin for 16 versus 24 Weeks in Patients with HCV Genotype 2 (11/03/2006)

 

In ACCELERATE Trial, Highest SVR Seen in Patients Who Received the Longest Duration of Therapy with Pegasys and the Highest Mean Dose of Ribavirin Based on Body Weight (11/03/2006)

 

Positive Impact of Higher Ribavirin Doses and Longer Duration of Therapy with Pegasys plus Ribavirin in HIV/HCV Coinfected Patients: The PRESCO Trial (11/03/2006)

 

Higher Doses of Both Pegasys and Ribavirin Improve Response Rates In "Difficult to Cure" Hepatitis C Patients (11/03/2006)

 

 

Insulin resistance and HCV: Will new knowledge modify clinical management?  (09/21/2006)

 

Insulin resistance and HCV: Will new knowledge modify clinical management? - (09/21/2006)
 
GAY MEN AND HEP C - (09/21/2006)

 

 

Peregrine's Final HCV Phase 1a Study Results Accepted for Oral Presentation at AASLD Annual Meeting - (08/16/2006)
 
Cost effectiveness of interferon or peginterferon with ribavirin for histologically mild chronic hepatitis C - (08/14/2006)
 

Coinfected with Normal ALT Have HCV Disease - (08/11/2006)

 

72 Weeks Pegasys/RBV Improves SVR for When HCV-RNA is Detectable at Week 4 - (08/09/2006)
 

Pegasys/RBV in African-Americans - (08/09/2006)
 

Pre-treatment LDL & T-Cholesterol Predict SVR in HCV+ - (08/08/2006)
 

Acute hepatitis C: Hi Dosage and compliance Predict SVR - (08/08/2006)
 

Interferon Enhancer Drug EMZ702 Study + PegIFN/RBV - (08/04/2006)
 

HCV RNA detection by TMA during the hepatitis C antiviral long-term treatment against cirrhosis (Halt-C) trial - (08/01/06)

 

Predictors of Sexual Transmission of HCV in Gay Men (08/18/06)

 

Relation between LDL Cholesterol Levels and Hepatitis C Treatment Outcomes  (08/18/06)

 

Diabetes is Associated with Hepatic Encephalopathy in Patients with HCV-Related Cirrhosis (08/18/06)

 

Pegylated Interferon Plus Ribavirin Therapy in Patients with HCV Recurrence after Liver Transplantation (08/18/06)

 

Non-invasive Assessment of Liver Fibrosis in Patients with Hepatitis C (08/15/06)

 

Long-term Effect of Interferon/Ribavirin on Incidence of Hepatocellular Carcinoma (08/15/06)

 

Thyroid Dysfunction in Chronic Hepatitis C Patients Treated with Interferon/Ribavirin (08/15/06)

 

Hepatitis C Virus Detection Using HCV RNA Qualitative (TMA) Testing in the HALT-C Trial (08/11/2006)


Tolerability and Efficacy of Pegasys/Ribavirin in Black Patients with Hepatitis C (08/11/2006)


Impact of Chronic Hepatitis C and Psychiatric Illness on Quality of Life (08/11/2006)


Compartmentalization of HCV in Plasma and Peripheral Blood Mononuclear Cells
24-Week vs 48-Week Treatment with Pegasys Plus Ribavirin in HCV Genotype 1 Patient (08/08/2006)


Comparison of Pegasys vs Peg-Intron for Treatment of Chronic Hepatitis C (08/08/2006)


Efficacy of Low-dose Peg-Intron (08/04/2006)

 

Pharmacokinetics and Antiviral Activity of Pegasys vs Peg-Intron (07/25/2006)
 

Chronic Arthritis Is Not Related to HCV Viral Load (07/25/2006)
 

Insulin Resistance and Diabetes in Patients with Chronic Hepatitis C (07/25/2006)
 

ALT Levels Prior to Pregnancy Predict Risk of HCV Vertical Transmission (07/21/2006)
 

Ophthalmological Side Effects of Hepatitis C Treatment are Related to Vascular Endothelial Growth Factor Levels (07/21/2006)

 

Impact of Alcohol Use on Hepatitis C Treatment Outcomes and Quality of Life (07/14/2006)

 

Drug Resistance Wksp: Hepatitis C virus resistance to new antivirals (07/11/2006)

 

Statin Drugs Inhibit HCV in vitro - (07/10/2006)

 

Vertex Pharmaceuticals and Janssen Pharmaceutica, a Johnson & Johnson Company, form collaboration to develop and market VX-950 for Treatment of Hepatitis C (06/30/2006)  

Vertex Pharmaceuticals and Tibotec Pharmaceuticals, a Johnson & Johnson Company, announce plans for global health initiative to increase worldwide prevention, diagnosis and treatment of HCV  (06/30/2006)
 
Phase 2 Study of VX-950, Pegasys, and Copegus in Hepatitis C- study sites  (06/30/2006)

 

Treating Hepatitis C in Patients with Pre-Existing Psychiatric Conditions (06/16/2006)
 

Coffee, Cirrhosis, and Transaminase Enzymes - (06/14/2006)
 
Drug Resistance Wksp: Selection and characterization of mutations conferring resistance to a HCV RNA dependent RNA polymerase inhibitor A-848837 in vitro - (06/14/06)
 

Drug Resistance Wksp: Merck's New HCV Polymerase Inhibitor Drug Reduces HCV Viral Load by 5.7 Log in 7 Days in Chimps - (06/14/06)
 
Coffee Consumption May Protect Liver from Alcohol - (06/13/06)

 

DDW 2006
New Phase 2 Studies (PROVE 1, 2 & 3) of  HCV Protease Inhibitor VX-950 Will Evaluate SVR Rates in Patients with HCV Genotype 1  (05-26-2006)

 

DDW 2006
In Nonresponders to Peginterferon/Ribavirin, Valopicitabine + Peginterferon at Optimal Dosing Produces Significantly Greater HCV Suppression Compared to Retreatment with Peginterferon Alfa

(05-26-2006)


DDW 2006
12 of 12 Patients Receiving Experimental HCV Protease Inhibitor VX 950 in Combination with Pegasys Plus Ribavirin for 28 Days Experience Undetectable HCV RNA Levels  (05-26-2006)

 

DDW 2006
Retreatment with Peginterferon Alfa-2a (Pegasys) Plus Ribavirin of Nonresponders with Cirrhosis/Advanced Fibrosis to Peginterferon Alfa-2b (PegIntron) (05/23/2006)

DDW 2006
Differences in Outcomes of Treatment with PegIntron Plus Fixed-dose or Weight-based Ribavirin Based on Genotype and Viral Load in HCV Genotypes 2 and 3 in The WIN-R Trial (05/23/2006)

 

 

EASL: Late-Breaker Studies from the 41st EASL on Treatment of Chronic Hepatitis C   (05/2/2006)


EASL: WIN-R Study Demonstrates Efficacy of Shorter PegIntron and Ribavirin Regimen in Hepatitis C Patients with Genotype 2 or 3 (05/2/2006)
 
EASL: Results of Pegasys ACCELERATE and REPEAT Trials (05/2/2006)


 EASL: New Oral Polymerase Inhibitor Shows Promising Results in Chronic Hepatitis C Patients


EASL: Effect of Pegasys Plus Ribavirin in Genotype 1 and 4 "Super-Responders"  (05/2/2006)


EASL: Library of Slides and Posters from EASL 2006 (05/2/2006)

 

EASL: Ritonavir Increases levels of Schering HCV Protease Inhibitor SCH503034 - (04/27/2006)
 

Vertex Adds 24-Week Arm to 12-Week VX-950 study - (04/26/2006)

 

 Novelos Therapeutics IND for Novel Hepatitis C Drug is Accepted by FDA; Company Is on Track to Begin Patient Enrollment by July 2006 - (04/24/06)
 

Entecavir 96 weeks in HBeAg(-), study ETV-027  (04/19/2006)

 

HCV Therapy Successful for With Mental illness/substance abuse  (4/12/2006)

 

 

 

Peginterferon Alfa and Ribavirin Combination Therapy is Safe and Effective in Chronic HCV Patients with Persistently Normal ALT Levels  (3/31/2006)
 

 

Black patients with chronic hepatitis C have a lower sustained viral response rate than non-Blacks with genotype 1, but the same with genotypes 2/3, and this is not explained by more frequent dose reductions of interferon and ribavirin  (03/21/2006)

 

 

Treatment-related Depression Is the Most Significant Factor Affecting Health-related Quality of Life in Chronic Hepatitis C  (3/21/2006)
 

Interim Results of Studies of Albuferon plus Ribavirin in Nonresponders and in Treatment-naïve Patients with HCV Genotype 1 (3/17/2006)

 

 

 

 Treatment with Peg-Interferon alfa-2b for HBeAg-Positive Chronic Hepatitis B: HBsAg Loss Is Associated with HBV Genotype (2/28/2006)

 

New Compound May Protect Against Liver Cancer (2/24/2006)

 

Enrollment Is Open to Study of Experimental HCV Protease Inhibitor SCH 503034 in Hepatitis C Patients Who Have Failed on Prior Treatment with Peginterferon/Ribavirin (2/17/2006)
 
Small Study Shows HCV RNA Levels Undetectable in 12 of 12 HCV Genotype 1 Patients after 4 Weeks of Treatment with Experimental Drug VX 950 Plus Pegasys and Ribavirin

(2/10/06)

 

Thalidomide in the treatment of HCV unresponsive to alfa-Interferon and ribavirin (2/9/2006)

 

CROI: Study fuels debate on role of GB virus C in HIV disease (2/8/206)

 

Early monotherapy with pegylated interferon alpha-2b for acute hepatitis C infection: The HEP-NET acute-HCV-II study  (02/8/2006)

 

Acute hepatitis C: In search of the optimal approach to cure  (02/8/2006)


Open Clinical Trial of New PI SCH 503034 Plus PegIntron in HCV Patients Nonresponsive to Prior Treatment with Peginterferon Plus Ribavirin  (2/7/2006)

 

Schering-Plough reports FDA grants Fast Track Designation to oral HCV protease inhibitor SCH 503034- (01/30/06)

 

Fatty liver (steatosis) may cause fibrosis & liver cancer - (01/30/06)
 

Acetaminophen (Tylenol, Paracetamol) overdose and liver damage IS easier than many realize - (01/30/06)
 
Hope of liver cancer blood test - (01/30/06)

 

New Antisense HCV Drug AVI-4065 in Study - (01/30/06)

 

 ViRexx to Present Hepatitis C Vaccine Data at HepDART 2005 - (12/14/05)

 

 

Treatment of Genotype 1 Chronic Hepatitis C: Increased Sustained Virological Response with High-dose RBV and Decrease of its Primary Side Effect, Anemia, Using Epoetin 

 

Peginterferon for HBV Therapy: review of studies

 

NIH Hepatitis B Management Conference: 2006

 

Technical considerations in liver transplantation: What a hepatologist needs to know (and every surgeon should practice) -

 

New HCV Protease Inhibitor
 

European Union's CHMP Adopts Positive Opinion for Shorter Course of PEGINTRON(R) and REBETOL(R) Combination Therapy for Certain Hepatitis C Patients with Genotype 1 and Low Viral Load
 

Phase I Study New Hep C Drug for Peg/RBV Nonresponders

 

Liver Biopsy vs Non-Invasive Blood Tests in HCV/HBV

 

New HCV Protease Inhibitor

 

Technical considerations in liver transplantation: What a hepatologist needs to know (and every surgeon should practice)

 

Cirrhotic Non-Responders Improve Liver Condition with Pegasys/RBV in APRICOT Study

 

Epoetin Alfa Once Weekly Improves Anemia in HIV/Hepatitis C Virus-Coinfected Patients Treated With Interferon/Ribavirin: A Randomized Controlled Trial

 

Pegylated Interferon Alfa-2a (Pegasys) with or without Ribavirin in HIV-HCV Coinfection
 

 

Prevalence of and risk factors for nonalcoholic fatty liver disease: The Dionysos nutrition and liver study

 

Innogenetics Confirms Three-Year Delay in Hepatitis C Vaccine Launch

 

Researchers create infectious hepatitis C virus in a test tube

 

Sexual transmission of HCV found in Swiss HIV-positive gay men

 

Acute Hepatitis C: Natural History and Response to Treatment with Pegylated Interferon and Ribavirin